Comparison between Intravitreal Bevacizumab and Triamcinolone Acetonide in Management of Diabetic Macular Edema

Simon A Siregar (1) , Elvioza Elvioza (2) , Andi A Victor (3) , Ari Djatikusumo (4) , Gitalisa A Andayani (5) , Anggun R Yudantha (6)
(1) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
(2) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
(3) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
(4) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
(5) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
(6) Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta , Indonesia
https://doi.org/10.35749/journal.v42i1.61

Article Sidebar

Issue
Vol. 42 No. 1 (2016): Ophthalmologica Indonesiana
Submitted
September 11, 2016
Published
September 11, 2016
FULLTEXT (PDF)

Abstract

Background: To critically evaluate the efficacy and safety profile of intravitreal bevacizumab (IVB)compared to intravitreal triamcinolone acetonide (IVTA) in patients with diabetic macular edema(DME).

Methods: We searched publication related to diabetic macular edema managed by bevacizumab andtriamcinolone acteonide through systematic search of database in a period of January 2002 untilOctober 2013. Information needed from all articles were extracted into a data extraction sheet. Wereviewed the efficacy of both treatment in decreasing central macular thickness (CMT), improvementof visual acuity and the adverse effects following the injection.

Results: Twelve articles were included after fulfilling inclusion and exclusion cirteria. Our analysisshowed single IVTA injection were more effective in decreasing CMT and improving visual acuity at1 week to 3 months. There were no significant improvement of CMT in multiple injection of IVTAcompared to multiple injection of IVB.

Conclusion: A single intravitreal injection of IVTA appears to offer certain short-term advantagesover IVB for the management of patients with diabetic macular edema, particularly with regard toCMT.

 

Keywords: intravitreal, triamcinolone acetonide, bevacizumab, diabetic macular edema

Full text article

Generated from XML file

Authors

Simon A Siregar
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
author@perdami.or.id (Primary Contact)
Elvioza Elvioza
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Andi A Victor
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Ari Djatikusumo
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Gitalisa A Andayani
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Anggun R Yudantha
Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta
Siregar, S. A., Elvioza, E., Victor, A. A., Djatikusumo, A., Andayani, G. A., & Yudantha, A. R. (2016). Comparison between Intravitreal Bevacizumab and Triamcinolone Acetonide in Management of Diabetic Macular Edema. Ophthalmologica Indonesiana, 42(1). https://doi.org/10.35749/journal.v42i1.61
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Copyright and license info is not available

Article Details

How to Cite

Siregar, S. A., Elvioza, E., Victor, A. A., Djatikusumo, A., Andayani, G. A., & Yudantha, A. R. (2016). Comparison between Intravitreal Bevacizumab and Triamcinolone Acetonide in Management of Diabetic Macular Edema. Ophthalmologica Indonesiana, 42(1). https://doi.org/10.35749/journal.v42i1.61